Back

Assessing residual cardiovascular risk in patients already treated with statin therapy.

7 April 2022 (16:15 - 16:25)
Organised by:
Congress Presentation Part of: Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl Treatment Open Access ESC Preventive Cardiology 2022

About the speaker

Photo
Professor Alberto Zambon

Padova University Hospital, Padua (Italy)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor U. Laufs (Leipzig, DE)
Slides
Presentation thumbnail
Exploring the role of icosapent ethyl based on current clinical evidence.
Professor J. Jukema (Leiden, NL)
Video
Presentation thumbnail
Icosapent ethyl: what are the most likely mechanisms of benefit?
Professor C. Packard (Glasgow, GB)
Video
Presentation thumbnail
Discussion.

Access the full session

Session thumbnail
Cardiovascular risk reduction beyond statin therapy: exploring the role of icosapent ethyl
Video

The Event

Event poster

ESC Preventive Cardiology 2022

7 April 2022 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Residual cardiovascular risk of patients with dyslipidemia receiving multifactorial cardiovascular prevention therapy
27 August 2021
thumbnail
Congress Presentation
Lipid-lowering therapies should be guided by vascular imaging rather than by plasma biomarkers – the final word.
26 August 2022
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation
Remnant cholesterol and its role in patients with coronary atherosclerosis evaluated by coronary CT
13 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources